FDA removes screening, monitoring requirement for acne drug

Washington - The Food and Drug Administration (FDA) has removed a blood-screening and monitoring requirement for Aczone, a topical acne treatment manufactured by QLT USA, a unit of biotech company QLT Inc., Vancouver, British Columbia, the Associated Press reports.

Prior to the FDA’s action, patients using the drug had to be monitored for blood conditions, including a type of anemia. According to the company, recent post-marketing studies show no clinical evidence of anemia in patients who have used the drug.